Elanco Animal Health Inc ELAN
Elanco Animal Health Inc (ELAN) earns a Piotroski F-score of 6/9 (mixed financial health). It does not currently pay a dividend. FY2025 revenue was $4.7B at a -4.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.68 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-06 | UBS | Buy (main) |
| 2026-08-06 | Keybanc | Overweight (main) |
| 2026-07-22 | Morgan Stanley | Equal-Weight (main) |
| 2026-06-18 | TD Cowen | Buy (main) |
| 2026-05-07 | Citigroup | Buy (main) |
| 2026-05-07 | JP Morgan | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ELAN | Elanco Animal Health Inc | 6/9 | — | — | +6.2% |
| JAZZ | Jazz Pharmaceuticals plc | 5/9 | 1.63 | — | +4.9% |
| PRGO | PERRIGO Co plc | 4/9 | -0.37 | — | -2.8% |
| ONC | BeOne Medicines Ltd. | 7/9 | 1.78 | — | +40.2% |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | 5/9 | -0.11 | 124 | +65.2% |
| BMRN | BIOMARIN PHARMACEUTICAL INC | 4/9 | 7.43 | 32.7 | +12.9% |
| OGN | Organon & Co. | 5/9 | — | 19 | -2.9% |
About Elanco Animal Health Inc
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
FAQ
Is ELAN financially healthy?
Elanco Animal Health Inc's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak).
Does ELAN pay a dividend?
No, Elanco Animal Health Inc does not currently pay a dividend.
How profitable is ELAN?
In FY2025, Elanco Animal Health Inc had a net margin of -4.9% and a return on equity of -3.5%.
What is the analyst price target for ELAN?
The average Wall-Street price target for Elanco Animal Health Inc is $31.21, about 41.0% above the recent price, from 14 analysts (consensus: strong buy).
Is ELAN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Elanco Animal Health Inc: a Piotroski F-score of 6/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.